K. Shan

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

L. Peyrin-Biroulet, S. Danese, J. Panés, 2023, Journal of Crohn's and Colitis.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

S. Vermeire, B. Sands, G. D'Haens, 2023, The Lancet.